Japan Lifeline Receives Approval for Proprietary Radiofrequency Transseptal Wire XEROstar

January 13, 2026

Company Name: Japan Lifeline Co., Ltd.

Representative: Keisuke Suzuki, President and CEO

(Security Code: 7575; TSE Prime Market)

Inquiries: Takeyoshi Egawa, Director and CFO

(TEL. +81-3-6711-5200)

TOKYO, JAPAN - January 13, 2026 - Japan Lifeline Co., Ltd. ("the Company") is pleased to announce that it has received regulatory approval for "XEROstar," a proprietary radiofrequency transseptal wire. The product is

scheduled for full market release starting as early as March 2026.

In the field of cardiac arrhythmias, which is the Company's area of expertise, catheter ablation has become a widespread procedure for treating atrial fibrillation-a common type of cardiac disease. This treatment requires a "transseptal puncture" (creating a small hole in the septal wall separating the heart's chambers) to pass the

therapeutic catheter from the right atrium to the left atrium. As this puncture is the first critical step in the entire procedure, high safety and certainty are essential.

XEROstar is a proprietary product designed to optimize both the workflow efficiency of transseptal punctures and safety. The product name, XEROstar (pronounced "Zero Star"), reflects its ability to enable a "zero exchange workflow" streamlining the procedure. Unlike conventional needle-type devices, XEROstar employs a flexible wire shape that allows physicians to complete the process -from creating the puncture to establishing the

transseptal pathway (sheath) from the right atrium to left atrium for the therapeutic catheter-using a single wire. This eliminates multiple device exchange steps required with conventional methods, contributing to shorter procedure times and improved procedural efficiency. Furthermore, the wire tip features a "half-pigtail"

configuration, which reduces the risk of accidental injury to the vessel wall after reaching the target left atrium.

Keisuke Suzuki, President and CEO of Japan Lifeline, commented as follows: "Since 2013, we have contributed to the expansion of transseptal puncture procedures in Japan by exclusively distributing a foreign manufacturer's product, covering over 90% of domestic atrial fibrillation cases. Although that partnership ended due to the

acquisition of the supplier, we have advanced in-house development to re-enter the market by translating years of accumulated expertise into the development of our proprietary catheter technology."

He continued, "I am delighted that we are now ready to launch XEROstar because of those efforts. This product is expected to create future synergies as it will be used not only for catheter ablation of atrial fibrillation but also in the structural heart disease field, which we have positioned as a strategic growth area. We highly expect that XEROstar will be widely accepted as a new option in clinical settings and will contribute significantly to procedural efficiency."

The impact of this matter on the Company's consolidated financial results for the fiscal year ending March 2026 is expected to be negligible.

Radiofrequency Transseptal Wire XEROstar

Japan Lifeline Co., Ltd. (Tokyo Stock Exchange Prime Market: 7575) is a medical device company specializing in the cardiac and cardiovascular fields. The company focuses primarily on electrophysiology catheters and vascular grafts. It builds its product portfolio through distribution operations that introduce superior overseas medical

devices to Japan. The company also develops and produces proprietary products through its manufacturing

capabilities. Operating through 48 domestic sales offices while expanding its proprietary products globally, Japan Lifeline provides the latest and most suitable medical devices to healthcare professionals and patients worldwide. For more information, visit: https://www.japanlifeline.com